154 related articles for article (PubMed ID: 38321201)
1. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.
García Vicente AM; Lucas Lucas C; Pérez-Beteta J; Borrelli P; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM
Sci Rep; 2024 Feb; 14(1):3001. PubMed ID: 38321201
[TBL] [Abstract][Full Text] [Related]
2. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in
Nickols N; Anand A; Johnsson K; Brynolfsson J; Borreli P; Parikh N; Juarez J; Jafari L; Eiber M; Rettig M
J Nucl Med; 2022 Feb; 63(2):233-239. PubMed ID: 34049980
[TBL] [Abstract][Full Text] [Related]
3. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [
Johnsson K; Brynolfsson J; Sahlstedt H; Nickols NG; Rettig M; Probst S; Morris MJ; Bjartell A; Eiber M; Anand A
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1041-1051. PubMed ID: 34463809
[TBL] [Abstract][Full Text] [Related]
4. Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.
García-Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38520513
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Fluorocholine in initial staging of intermediate-/high-risk prostate cancer: a pilot study.
Lucas Lucas C; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Ann Nucl Med; 2023 Oct; 37(10):551-560. PubMed ID: 37532975
[TBL] [Abstract][Full Text] [Related]
6. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using
Gafita A; Bieth M; Krönke M; Tetteh G; Navarro F; Wang H; Günther E; Menze B; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(9):1277-1283. PubMed ID: 30850484
[TBL] [Abstract][Full Text] [Related]
7. Prospective Evaluation of
Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
[No Abstract] [Full Text] [Related]
8. Repeatability of Quantitative
Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted
Wang F; Liu C; Vidal I; Mana-Ay M; Voter AF; Solnes LB; Ross AE; Gafita A; Schaeffer EM; Bivalacqua TJ; Pienta KJ; Pomper MG; Lodge MA; Song DY; Oldan JD; Allaf ME; De Marzo AM; Sheikhbahaei S; Gorin MA; Rowe SP
J Nucl Med; 2024 Jan; 65(1):87-93. PubMed ID: 38050147
[TBL] [Abstract][Full Text] [Related]
10. A Pilot Study of Dynamic
Lu M; Lindenberg L; Mena E; Turkbey B; Seidel J; Ton A; McKinney Y; Eclarinal P; Merino M; Pinto P; Choyke P; Adler S
Mol Imaging Biol; 2022 Jun; 24(3):444-452. PubMed ID: 34724140
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. SUVs Are Adequate Measures of Lesional
Bodar YJL; Koene BPF; Jansen BHE; Cysouw MCF; Meijer D; Hendrikse NH; Vis AN; Boellaard R; Oprea-Lager DE
J Nucl Med; 2021 Sep; 62(9):1264-1269. PubMed ID: 33509971
[TBL] [Abstract][Full Text] [Related]
13. Detection of prostate cancer with
Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
[TBL] [Abstract][Full Text] [Related]
14. Role of
Zhang T; Yang S; Lin L; Wang S; Xia D; Chen D; Wang G; Zhao K; Su X
Hell J Nucl Med; 2022; 25(1):11-18. PubMed ID: 35388799
[TBL] [Abstract][Full Text] [Related]
15. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
16. Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.
Liu Y; Zhang X; Liu J; Zhang J; Xu B
Nucl Med Commun; 2022 Jun; 43(6):725-730. PubMed ID: 35560134
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract][Full Text] [Related]
18. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
19. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
[TBL] [Abstract][Full Text] [Related]
20. Pathological predictors of
Perry E; Talwar A; Taubman K; Ng M; Wong LM; Sutherland TR
BJU Int; 2022 Jun; 130 Suppl 1(Suppl 1):28-36. PubMed ID: 35768883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
